A modified dosing regimen of donanemab led to a 41% reduction in the risk of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in early symptomatic Alzheimer's patients, according to a recent study.
The Phase 3b study found that 14% of patients receiving the modified titration experienced ARIA-E, compared to 24% in those on the standard dosing regimen, according to an Oct. 29 news release from the company. The modified approach allows for once-monthly dosing while maintaining amyloid plaque clearance.
Donanemab was approved by the FDA in July under the brand name Kinsula. Eli Lilly plans to discuss the findings with global regulators and may seek a label update for Kinsula, the release said.